Amarin Corporation PLC (AMRN) Options

Yes, that is certainly possible.

CCSB in Taiwan is a well known supplier of API to the generics. They were one of the first to get qualified in the initial ANDAs. Maybe recent shipments haven't come from there, but they have in the past and could in the future. It's rare for any manufacturer of anything to be locked in to one sole qualified supplier for a critical material. They'll have contingencies and options mapped out. The potential for tariffs hitting has been discussed for months before they actually rolled out giving them time to seek options in other regions. Adding an already FDA qualified API supplier to your DMF and filing it isnt that hard so them going after sourcing in SK, Japan and EU should be expected.

JR Its also possible ( imho likely ) that Hikma , Teva etc stockpiled API in anticipation of these tariffs and also had diversified their supply sources beyond China to some extent ( Taiwan being an obvious choice )
Good luck
Kiwi

On LinkedIn:
https://www.linkedin.com/posts/michael-everts-34799334_look-whats-on-the-menu-european-atherosclerosis-activity-7320081844081737728-V4e1?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAdDmycBzT_CwLIulyFqANe8SLMF4KH2Odo

On X:
Look what's on the Menu @society_eas @EASCongress 2025: @SABOURETCardio @DLBHATTMD @VietHeartPA @drpablocorral @drlipid @gabrielsteg #EAS25 😉😉😉 pic.twitter.com/uNe41YSllP— Mike Everts (@GeoWizz_) April 21, 2025

https://stocktwits.com/SanDiegoLiving/message/612106901

https://stocktwits.com/SanDiegoLiving/message/612139796

https://stocktwits.com/SanDiegoLiving/message/612139844

Look what's on the Menu at EAS 2025 May 4-7:
It's the Endoplasmic Reticulum Stupid!

Kiwi, it is possible that at the time of the lawsuit being filed, that they may have had agreements with Taiwanese suppliers. But the current suppliers we see are all from mainland China. That's not to say that they could not shift their supply chain back to Taiwanese suppliers - which I am sure they would do eventually, if it is enough of a financial burden to remain with China. But there is likely a reason that they shifted to Chinese suppliers (ie. less expensive). So if they shifted BACK, it is likely more expensive, and they may have penalties for exiting/modifying their current supply deals (not unlike what happened to Amarin).

Yet one more reason why the new formulation is so important. Most people don't enjoy taking 4 large caps a day, on top of other medications and supplements they are already taking. ( Ezetimbe ) otherwise known as Zetia ....it's a small pill and easy to take .

You Rock Capt'n

https://www.linkedin.com/feed/update/urn:li:activity:7319693125017374720?commentUrn=urn%3Ali%3Acomment%3A%28activity%3A7319693125017374720%2C7319757824048209920%29&dashCommentUrn=urn%3Ali%3Afsd_comment%3A%287319757824048209920%2Curn%3Ali%3Aactivity%3A7319693125017374720%29

What would you do Kiwi without AI ??

Denisk. thx for that link. I think N7 has been tracking this .
I noted that the info I was posting was from Grok ...and that said Hikma and Dr Reddy were importing from Taiwan .
Hikma , Dr Reddy and Teva probably have multiple sources .
Not trying to spread rumors and welcome any correction

From Perplexity
Teva and Hikma's API Sources for Generic Vascepa
Background on API Supply Challenges
Both Teva and Hikma have accused Amarin, the originator of Vascepa (icosapent ethyl), of engaging in anti-competitive practices by locking up the supply of the active pharmaceutical ingredient (API) through exclusive contracts with suppliers. This strategy allegedly made it difficult for generic manufacturers to secure sufficient quantities of icosapent ethyl for their own products.
Hikma's API Source
According to recent industry commentary, major generic manufacturers like Hikma have primarily sourced their icosapent ethyl API from CCSB in Taiwan.
There is also mention that, due to tariffs on Chinese-sourced API, companies may shift away from Chinese suppliers and look to alternative sources, such as CCSB in Taiwan or European suppliers.
Teva's API Source
While the search results do not explicitly name Teva's API supplier, the context suggests Teva faced similar difficulties as Hikma in securing API due to Amarin's exclusive supply agreements.
It is reasonable to infer that Teva, like Hikma, would seek out non-exclusive suppliers such as CCSB in Taiwan or potentially European API manufacturers, especially given the challenges with Chinese API tariffs and Amarin's control over other sources.
Summary Table
Company Primary API Source (Generic Vascepa) Notes
Hikma CCSB (Taiwan) Sought alternatives due to Amarin's exclusivity and Chinese tariffs
Teva Likely CCSB (Taiwan) or EU sources Faced similar supply barriers as Hikma; likely uses same or similar suppliers
Key Points
Both Teva and Hikma have faced significant barriers in sourcing icosapent ethyl API due to Amarin's exclusive contracts with suppliers.
CCSB in Taiwan is identified as a key API supplier for Hikma and likely for Teva as well, especially as tariffs and exclusive agreements limit other options.
The situation remains dynamic, with supply chain pressures and trade policies influencing sourcing decisions.

Kiwi

I am not so sure you are correct . Hikma imports from China:
On March 23, 2025 Hikma shipped 38160 kg of Icosapent ethyl from their supplier Resolution Limited via SEA Air from China to Norfolk VA, USA, that's for sure not Taiwan.
So where do you get that info about Taiwan?? Can you send proof of what you posted? or just trying to spread rumors on this blog?

https://www.seair.co.in/us-import/product-icosapent-ethyl.aspx

Tats. speaking of Easy-E ( Ezetimbe ) otherwise known as Zetia ....it's a small pill and easy to take .
Since Kaiser is currently unable to fill Repatha scripts ( dont know if thats a tariff thing or not ) ....and insists patients like me pay full price for Inclisiran ( Leqvivo )..the other PCSK 9 ...looks like I'm on Crestor / generic Vascepa / Zetia starting next week.
Kiwi

Annual report 2024 filed (UK)
https://find-and-update.company-information.service.gov.uk/company/02353920/filing-history

It was not me, since I sold at 13. But I convinced another 100k shareholder to sell at 20 for 2m and buy 1000 $20 strikes instead for 300k. This way, his maximum loss was 300k instead of riding back to 3, which I saw as possible if they lost the case. I was unable to convince another 100k holder to do the same, and he got angry at me. I have not spoken to him since.

Thx Tats ...on further investigation
CCSB (Taiwan): Major generic manufacturers like Hikma Pharmaceuticals and Dr. Reddy’s have primarily sourced their icosapent ethyl API from CCSB in Taiwan......from Grok
Taiwan and the EU I believe currently have the same tariff rate ...Soooooo ...apparently no advantage to AMRN despite my original hopes
Correct if necessary
Kiwi

ORBAPU, Anyone know if the - 'JL' your talking about - 'is still around and breeding' ?
------------------------

Remember how this guy bragged (in other forums) about having made more than $1,5 mill. dollars on AMRN - out at around $18 using options' - to protect himself before the disastrous Nevada Court Ruling ?

Wish I had his brains 🙂

Cool. Vascepa fighting with Omacor over 5k Rx a month while BA and Eazy-E run away with it....

Meant to say majority of the retail share holders will not vote, even if they make up for more than 75% of the total float

Did exactly the same thing for all my shares and it’s some decent volume. It’s unfortunate that majority of the retail shareholders will note, does not bother to vote or don’t know that they have the right to vote. However a good volume of no votes will actually send a very strong message that retail shareholder are very disappointed, and if united can boot out the board.

The opinion looks to be about 50/50 on sports related posts. I don't intend to delete any unless they start to clog the board.
Sleven,

Sleven, got it, I stopped reading the same old rhetoric a while back. Thanks

Good morning my $AMRN Friends. In case you missed my monthly Summary of the UK EPD (English Prescribing Data) a few days ago here’s a repeat with an additional SLIDE #3

SLIDE# 1
Monthly capsules or tablets dispensed in England for (4) non-statin agents with percent changes from the previous month (January 2025)

SLIDE# 2
Monthly Market Share comparison between VAZKEPA® and OMACOR (mixed EPA/DHA and non-reimbursed and not recommended) Note: We should take Market Share in April.

Slide# 3
This slide illustrates the under-utilization of VAZKEPA® in the UK. NICE estimates a TAM for VAZKEPA® at 425,000 patients. VAZKEPA®’s current TAM is

IF any tariff on Chinese API stays in effect ...big for AMRN longs

What's going to stop the generic manufacturers from sourcing API from existing suppliers in South Korea, Japan and the EU if there's a tariff advantage?

Lizzy, Of course. I intend to use my best judgement. I think most of the people here understand the sort of political posts that we are talking about.
Sleven,

MrFred, Got it.
Sleven,

ORBAPU, similar story to my optometrist recommending omega 3 after cataract surgery to enhance healing. After researching my options, I discovered V.

Recall Jesse Livermore talking about his plastic surgery patients having less bruising and bleeding and faster recovery with Vascepa. 

Not sure what you mean by that but the share price was $4 on that date and that was before this RS.  So the equivalent of $80. 

Sleven, for what it's worth, IMHO, politics relating to the pharmaceutical industry is important to the Amarin board. How about a compromise? If pharmaceutical news affects our company, we can post the information to justify the cause and effect. But a pure political post should be banned.

Hey Steven, remember your rules?  No political posts! LOL

"All of the libtards that I talk to think I'm a right wing asshole. All of the retrumplicans think I'm a libtard."

https://stocktwits.com/SanDiegoLiving/message/612086303

Nsleven, I agree with Mauiguys comments and would vote to allow the sports talk.

On March 31, 2020 the price of AMRN stock was $4.00 as adjusted to current shares price.
https://markets.financialcontent.com/stocks/quote/historical?Month=4&Year=2020&Symbol=537%3A3704787&Range=3

Received AGM Shareholder voting proxys today. I voted NO today on all items except to retain E&Y as auditors. IMO, this team has not delivered shareholder value; instead this team has wiped out 95% of all shares of stock. Losses locked in. Lack of communications and transparency. Weak CEO, should have been fired after he lost the U.S. CVS contract in 2024. Vote them out with the only Shareholder tool available; VOTE.

Mauiguy, got it.
Sleven,

The EPA oxylipin, 12-HEPE, directly regulates human platelet activity
Available online 16 April 2025
https://www.sciencedirect.com/science/article/pii/S0022227525000677

Implications for Cardiovascular Health
These findings explain how EPA supplementation—widely used for cardiovascular risk reduction—achieves its benefits: by converting to 12-HEPE in platelets, it powerfully suppresses platelet-driven thrombosis. Understanding this pathway supports targeted use of EPA/12-HEPE levels as biomarkers or therapeutic agents to prevent heart attacks and strokes.

I was away yesterday and didn't see your sports talk survey. Maybe it's too late to express my view, but I'll do it anyway.

I don't think there's an excessive amount of sports talk on this board.....perhaps on a Monday morning during football season and occasional basketball talk. But, like I say, it's not excessive. Sports talk NEVER leads to heated discussions or personal attacks on this board.

I vote allowing sports talk to continue.

RMB, one can only hope that something gets done to correct the insurance and PBM's money grab.

I can almost talk myself into buying AMRN again .
No FFS I'm not catching a falling knife .
If these tariffs stay in effect Kaiser et al will switch to EU API sourced Vascepa ...if they can get out of their existing supply contracts for IPE ...which they probably can if those suppliers declare force menjure
Kiwi

Tariffs on goods imported from China to the US are collected on arrival in the US, not before the Chinese supplier ships. Here's how it works:
US Customs Service: When goods arrive at a US port of entry, the US Customs Service assesses and collects the tariffs. The importer of record (typically the buyer or their designated customs broker) is responsible for paying the tariff.

Process: The importer submits documentation (e.g., commercial invoice, bill of lading) to US Customs, which determines the tariff based on the Harmonized Tariff Schedule (HTS) code and the applicable rate, including any additional tariffs (e.g., Section 301 tariffs on Chinese goods).

Payment: Tariffs are paid to US Customs before the goods are released for entry into the US. This is typically handled by the importer or their broker, and the cost may be passed on to the buyer or absorbed, depending on the terms of sale (e.g., Incoterms like DDP or FOB).

Chinese Supplier Role: The Chinese supplier is not responsible for US tariffs. Their role ends once the goods are shipped, unless the sales terms specify otherwise (e.g., Delivered Duty Paid, where the supplier covers duties).

For example, if you're importing electronics from China, you or your customs broker would pay the tariff (e.g., 25% under Section 301) when the goods clear US Customs, based on the declared value of the shipment.


Kiwi

The Co importing it pays . I was reading a post from a guy that had a small company importing playground structures made in China .
Thats was his business . He imports them then contracts with schools , towns etc to install them .
He posted a bill on his first 20% tariff charge . He had to pay $16 K for what he had ordered ..plus at the time ...this was 30 days ago ...20% on top of that as a tariff charge .
Sorry I forget who he was paying the tariff to ...maybe the supplier who would not ship until he had paid .
Said with a 140% tariff he's effectively out of business

So expect the Chinese API suppliers to begin issuing force menjures to either get out of their contracts or pass the tariff charges along .
They will have already seen the 20% tariffs in force earlier
With 140% tariffs it will be a huge increase in IPE/ Vascepa imported API from any Chinese source .
Question is how long thats stays in effect and if Kaiser et al will switch to Co's sourcing API from the EU

Kiwi

Well the irony is that the Tesla Y I drive is about the most American made car on the road . But I've taken to driving my old pick up with the gun racks more lately ...It's dented enough that I dont care if it gets key'd .
Sorry , can't think of anything AMRN related in this post other than Trump should be on Vascepa .
He's already on a Statin plus Zetia ...add the V man ...just do it
Kiwi

RMB, The US company importing a product pays the Tariffs. A tariff is a tax imposed on the importer. This is a massive tax imposed on American companies. It will be passed to American consumers. We have a trade deficit because China can't afford our products. Think it through. It will increase the cost for generic companies that get supplies from China. It might push them out of the market.
Sleven,

I am just trying to figure out who pays that tariff and where. Supposedly the US Immigration and Customs Dept (I may not have the correct name) has been collecting it. So if a Chinese API supplier ships to the U.S., do they pay it or the company importing the API? And, is it going directly to the Generics (Hikma, etc). Ultimately we assume the cost gets passed along to the Generics. They then I assume go crying to the insurers or PBMs and say they need more for their IPE. The way you posit it, then the insurers say Sayonara to the Generics and call up Amarin for supply and start covering V. That it?

RMB, Thank you.
Sleven,

Sleven, that's when you know you are right where you should be.